Cybin, Inc. (TSE:CYBN) has released an update.
Cybin Inc.’s CEO, Doug Drysdale, will participate in a mental health panel at the prestigious 27th Annual Milken Institute Global Conference. The company, known for developing psychedelic-based treatments for mental health disorders, will use this platform to discuss their innovative work, including two promising compounds, CYB003 and CYB004, which are advancing through clinical trials. Cybin’s involvement showcases their commitment to transforming mental healthcare through novel therapeutics.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
